11115070

Source:http://linkedlifedata.com/resource/pubmed/id/11115070

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0018270, umls-concept:C0026809, umls-concept:C0086418, umls-concept:C0151650, umls-concept:C0332293, umls-concept:C1510411
pubmed:issue	6
pubmed:dateCreated	2000-12-21
pubmed:abstractText	The biologic responses to transforming growth factor-beta (TGF-beta) suggest many potential therapeutic applications; however, in the only clinical trial to examine the effect of the systemic administration of a TGF-beta isoform, patients experienced significant but reversible declines in renal function. We studied the effects of administering human recombinant TGF-beta2 to adult mice.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0323470
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II, http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1, http://linkedlifedata.com/resource/pubmed/chemical/Procollagen, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/TGFB2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta, http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta2
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	0085-2538
pubmed:author	pubmed-author:DoyleSS, pubmed-author:KurtzbergLL, pubmed-author:LedbetterSS, pubmed-author:PrattB MBM
pubmed:issnType	Print
pubmed:volume	58
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2367-76
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:11115070-Angiotensin II, pubmed-meshheading:11115070-Animals, pubmed-meshheading:11115070-Anoxia, pubmed-meshheading:11115070-Corrosion Casting, pubmed-meshheading:11115070-Endothelin-1, pubmed-meshheading:11115070-Fibrosis, pubmed-meshheading:11115070-Glomerular Filtration Rate, pubmed-meshheading:11115070-Humans, pubmed-meshheading:11115070-Ischemia, pubmed-meshheading:11115070-Kidney, pubmed-meshheading:11115070-Kidney Diseases, pubmed-meshheading:11115070-Male, pubmed-meshheading:11115070-Mice, pubmed-meshheading:11115070-Mice, Inbred C57BL, pubmed-meshheading:11115070-Mice, Inbred ICR, pubmed-meshheading:11115070-Procollagen, pubmed-meshheading:11115070-Recombinant Proteins, pubmed-meshheading:11115070-Transforming Growth Factor beta, pubmed-meshheading:11115070-Transforming Growth Factor beta2, pubmed-meshheading:11115070-Vasoconstriction
pubmed:year	2000
pubmed:articleTitle	Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2.
pubmed:affiliation	Genzyme Corporation, Framingham, Massachusetts 01701, USA. steve.ledbetter@genzyme.com
pubmed:publicationType	Journal Article